In The News
May 22, 2024

Women @ RopesTalk: Conversation with Svetlana Lucas, Scribe Therapeutics

Women @ RopesTalk Podcast – Svetlana Lucas, PhD, shares her journey in the biotech industry, the challenges and opportunities she has encountered, and her insights on the future of CRISPR technology. She also discusses the importance of relationships, diversity, and mentorship in the industry, and embracing the concept of “being comfortable with being uncomfortable.”

Read More
May 2, 2024

DNA: Cutting the Future of Genome Editing

The Biomedical Scientist – Biotechnology company Scribe Therapeutics builds CRISPR, genome-editing and other types of genetic modification technologies for different conditions, including cardiometabolic disease.

Read More
April 12, 2024

CRISPR technologies fuelling haematological innovations

European Pharmaceutical Review – GlobalData highlighted that the largest CRISPR-based deal of 2023 was Eli Lily’s subsidiary, Prevail Therapeutics gaining rights to Scribe Therapeutics’s CRISPR X-Editing (XE) technologies. In a deal potentially worth over $1.57 billion, the agreement seeks to advance in vivo therapies for targets that cause serious neurological and neuromuscular diseases.

Read More
March 5, 2024

Benjamin Oakes and the Promise of CRISPR

Sounds of Science – Benjamin Oakes, scientist, entrepreneur, and co-founder of Scribe Therapeutics, appears on Eureka’s Sounds of Science to discuss his personal vision for the future of CRISPR, encouraging advances in the field, and the first ever drug approval for a CRISPR based therapy.

Read More
February 20, 2024

CRISPR by Design with Benjamin Oakes

Raising Health – Scribe Therapeutics cofounder and CEO Benjamin Oakes, PhD, joins a16z Bio + Health founding general partner Vijay Pande on a16z Bio + Health podcast Raising Health.

Read More
February 20, 2024

CRISPR Partnerships Propel Precision Medicine

CRISPR Medicine News – Meanwhile, the high-risk bone marrow ablation required for diseases like sickle cell disease and beta-thalassemia is driving innovation towards in vivo genome editing, with companies like Scribe Therapeutics and Sanofi embarking on a $1.24 billion venture to develop more precise and deliverable Cas endonucleases.

Read More
February 19, 2024

A CRISPR collaboration compilation

Nature Biopharma Dealmakers – Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.

Read More
January 17, 2024

A road to survival

ASBMB Today – Outside of academia, companies including Scribe Therapeutics are also developing gene therapies for diseases such as sickle cell.

Read More
December 21, 2023

Peer Review

Endpoints News – The California-based CRISPR biotech has tapped Aarif Khakoo as CSO and head of R&D, and appointed Maria Mirotsou as VP of discovery biology.

Read More
December 8, 2023

FDA approves CRISPR–Cas9 therapy for sickle cell disease

ASBMB Today – Benjamin Oakes, CEO and cofounder of Scribe Therapeutics, said “The approval is just the tip of the iceberg. It’s a really beautiful proof of concept for what CRISPR genome editing can do. … The real vision and mission for the whole CRISPR field should be to create safer, more effective therapies that can be brought more broadly to patients.”

Read More
July 17, 2023

Sanofi goes back to Scribe

Evaluate Vantage – The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.

Read More
May 19, 2023

Scribe Inks CRISPR Gene-Editing Deal with Prevail

Bloomberg Technology – CRISPR pioneer Jennifer Doudna’s company Scribe Therapeutics inked a major deal with Prevail Therapeutics potentially worth $1.5 billion to create genetic medicines for neurological and neuromuscular diseases. Scribe CEO Ben Oakes joins Caroline Hyde for more.

Read More
May 16, 2023

Scribe pens $1.5B-plus CRISPR tech deal with Lilly

BioWorld – Scribe Therapeutics Inc. is selling exclusive rights to its CRISPR-based technology to Prevail Therapeutics Inc. for a figure that could top $1.6 billion as the firms team up to develop genetic therapies for serious neurological and neuromuscular diseases.

Read More
April 11, 2023

The New Age of CRISPR

I am BIO Podcast – CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. This episode features scientists working to push these gene editing tools to the next frontier.

Read More
January 6, 2023

Economic Forecast 2023

San Francisco Business Times – Tapping the power of the CRISPR genome-editing technology, Alameda-based Scribe Therapeutics recently signed a deal with drug maker Sanofi to enable genetic modification of novel “natural killer” cell therapies for cancer.

Read More
October 18, 2022

Deals In Depth: September 2022

In Vivo – In September, Sanofi received non-exclusive rights to use Scribe Therapeutics, Inc.’s proprietary CRISPR genome editing technologies and platform of wholly owned enzymes to create ex vivo natural killer cell therapies for cancer.

Read More
September 28, 2022

Follow the Money

Bio-IT World – The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies.

Read More
September 27, 2022

Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration

Genetic Engineering and Biotechnology News – Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today, through a collaboration that could generate more than $1 billion for the CRISPR drug developer whose co-founders include Nobel laureate Jennifer Doudna, PhD, of UC Berkeley.

Read More
June 29, 2022

Innovators Under 35 2022

MIT Technology Review – As CEO of Scribe Therapeutics, Benjamin Oakes, 33, is working to optimize novel CRISPR enzymes and ways to package the gene-editing systems to solve those problems.

Read More
May 4, 2022

Biogen Pursues Another Neuro Target With Scribe

Inside Precision Medicine – Biogen has exercised an option for an additional disease target in gene therapy with Scribe Therapeutics. This is part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based therapeutics.

Read More
May 3, 2022

Scribe, Biogen expand ALS CRISPR agreement

Pharma Manufacturing – Scribe, headquartered outside of San Francisco, focuses on creating gene therapies using CRISPR technology and custom engineered enzymes. The company’s custom platforms help it to overcome the technological hurdles that other companies in the field face, said Oakes.

Read More
March 25, 2022

CFOs On the Move

CFO – Biotech firm Scribe Therapeutics appointed David Parrot as chief financial officer. Parrot joins the company from Barclays, where he was a managing director responsible for building its West coast life sciences and biotechnology investment banking business.

Read More
March 11, 2022

Chutes & Ladders

Fierce Biotech – David Parrot is the new CFO of Scribe Therapeutics, a molecular engineering company focused on CRISPR-based meds, after serving as a managing director at investment bank Barclays.

Read More
March 11, 2022

Peer Review

Endpoints News – One of Jennifer Doudna’s CRISPR startups, Alameda, CA-based Scribe Therapeutics, has corralled David Parrot as CFO and George Manning as controller.

Read More
March 11, 2022

BioSpace Movers & Shakers

BioSpace – Life sciences companies continue to bolster their leadership teams as they prepare for the next phase of growth.

Read More
March 10, 2022

Venture Investment in Crispr Gene Editing Spurs Innovation, Hunt for IP

The Wall Street Journal – Scribe Therapeutics Inc., an Alameda, Calif.-based biotech startup also co-founded by Dr. Doudna, is developing custom-engineered enzymes for Crispr-based treatments for neurodegenerative and other diseases. Scribe’s technologies are distinct from earlier approaches, co-founder and CEO Benjamin Oakes said.

Read More
March 10, 2022

Management Tracks

BioCentury – Scribe Therapeutics Inc. hired David Parrot as CFO. Parrot was managing director, head of west coast life science investment banking at Barclays Investment Bank. Scribe is developing custom enzymes and delivery modalities for CRISPR and was co-founded by Jennifer Doudna.

Read More
March 10, 2022

Appointments and advancements

BioWorld – Scribe Therapeutics Inc., of Alameda, Calif., appointed David Parrot chief financial officer and George Manning controller.

Read More
January 5, 2022

Novel Gene Editing Systems Come Into Their Own

Genetic Engineering and Biotechnology News – Scribe scientists hone CasX enzymes so that they acquire characteristics such as enhanced specificity. Oakes describes this as an “engineering first” philosophy, where the desired properties of the system are chosen in advance and intentionally designed, rather than being left to chance or nature.

Read More
October 26, 2021

Biocom Catalyst Awards

Biocom California – Scribe Therapeutics CEO Benjamin Oakes selected as a winner of the 6th annual Catalyst Awards.

Read More
April 12, 2021

5 Novel Therapies Using Synthetic Biology

Nanalyze – The company has raised a whopping $120 million from the likes of Andreessen Horowitz to build out a suite of CRISPR technologies designed to treat genetic diseases.

Read More
April 8, 2021

Engineering CRISPR with Ben Oakes

a16z Bio Clubhouse – a16z general partners Vineeta Agarwala and Vijay Pande talk to guest Ben Oakes, cofounder, President and CEO of Scribe Therapeutics in a conversation on the power of engineering gene editors, the transition from academia to a startup, and how to select the first indication to target with a novel bio platform.

Read More
March 31, 2021

Engineering the Future of Genetic Medicine

Technology Networks – Scribe Therapeutics co-founder and CEO Benjamin Oakes sat down for an interview on the company’s next steps in “fulfilling the promise of CRISPR” and how it will navigate some of the challenges associated with developing CRISPR-based therapeutics, including efficacy, scale-up and high costs.

Read More
December 14, 2020

2020 Was the Turning Point for CRISPR

Medium – Future Human – Scribe Therapeutics of Alameda, California, is using yet another form of CRISPR dubbed X-editing. Co-founded by CRISPR pioneer and Nobel winner Jennifer Doudna, PhD, the company will use the new gene-editing tool to develop treatments for neurological diseases.

Read More
November 3, 2020

Doudna’s Scribe unveils

Nature Biotechnology – Startup Scribe Therapeutics, spun out of Jennifer Doudna’s lab, emerged from stealth on 6 October with a next-generation CRISPR technology, armed with a $20-million series A round and a collaboration with Biogen.

Read More
October 20, 2020

8 Biocom Member Companies Leveraging CRISPR Technology

Biocom – Another of Doudna’s spin-outs, Scribe Therapeutics, just recently announced their plans to build a platform for CRISPR-based genetic medicine to create therapies for diseases like genetically driven ALS. The company’s tools and mission have the potential to dramatically accelerate CRISPR’s applications into the clinical setting.

Read More
October 8, 2020

CRISPR-Based ALS Treatment Being Developed by Scribe and Biogen

Genetic Engineering & Biotechnology News – Best known for her pioneering work in the discovery of CRISPR, Jennifer Doudna, PhD, professor at the University of California, Berkeley, doesn’t stop or, it seems, even slow down. As of yesterday morning, Doudna can add “accept Nobel Prize” to her to-do list as she, along with Emmanuelle Charpentier, PhD, was awarded the 2020 Nobel Prize in Chemistry.

Read More
October 8, 2020

Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

ALS News Today – Founded by the scientists who originally invented CRISPR, Scribe has developed novel, custom-CRISPR tools, using a technology called X-Editing. This advanced gene-editing platform has greater editing activity and higher specificity, meaning that it can edit the target gene with greater precision than other CRISPR tools currently available.

Read More
October 7, 2020

Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles

FierceBiotech – CRISPR evolved in bacteria as a form of “genetic vandalism,” as George Church, Ph.D., puts it, to fend off pathogens. That means it works very well in bacteria but runs into various obstacles when researchers try to put it to work in humans. Jennifer Doudna’s latest CRISPR company plans to surmount those hurdles with an entirely new CRISPR platform that does not rely on molecules found in nature.

Read More
October 6, 2020

Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story

BioWorld – Scribe Therapeutics Inc., another CRISPR-based genome editing firm out of the Jennifer Doudna stable, launched with $20 million in series A funding and a deal with Biogen Inc. in amyotrophic lateral sclerosis (ALS), which brings in another $15 million up front and up to $400 million in development and commercial milestones.

Read More
October 6, 2020

Scribe: engineering CRISPR’s next generation

BioCentury – Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts.

Read More
October 6, 2020

CRISPR startup Scribe Therapeutics lands big Biogen deal

San Francisco Business Times – Hoping to take the CRISPR genome-editing tool to the next level of drug development, startup Scribe Therapeutics Inc. said Tuesday that it landed a potential $400 million neurodegenerative disease deal with Biogen Inc.

Read More
October 6, 2020

Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter

Xconomy – The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments use the CRISPR system as scientists found it in nature, which means it still has limitations when applied to humans, says Benjamin Oakes, CEO of Scribe Therapeutics.

Read More
October 6, 2020

Scribe Therapeutics launches to explore next-generation CRISPR technology

Chemical & Engineering News – Scribe Therapeutics, a biotech firm focused on developing next-generation gene-editing technology, has raised $20 million in its first major round of financing, backed by Andreessen Horowitz. The firm separately unveiled a deal with Biogen to develop CRISPR-based treatments for amyotrophic lateral sclerosis (ALS).

Read More
October 6, 2020

Scribe Therapeutics launches a platform for engineering CRISPR-based therapeutics

TechCrunch – A new company called Scribe Therapeutics founded by two former members of CRISPR pioneer Jennifer Doudna’s UC Berkely genetics lab (alongside Doudna herself) launched on Tuesday, debuting a platform designed specifically to help develop and engineer new therapeutics based on CRISPR for addressing specific diseases, with permanent treatments in patients.

Read More
December 2, 2019

C&EN’s Year in Pharma 2019

Chemical & Engineering News – Jennifer Doudna’s lab at the University of California, Berkeley, published a detailed study on a genetically and structurally distinct CRISPR enzyme called CasX, which makes staggered breaks during its cutting of the DNA double helix.

Read More
More Headlines
Press Releases
May 10, 2024

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

Scribe Therapeutics Inc. presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, MD, and virtually.

Read More
April 22, 2024

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.

Read More
March 6, 2024

Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that co-founder and CEO Benjamin Oakes, Ph.D., and CFO David Parrot will participate in the upcoming Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and Wednesday, March 13, 2024 in Miami Beach, FL.

Read More
December 20, 2023

Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the appointments of Aarif Khakoo, M.D., M.B.A., as Chief Scientific Officer and Head of Research and Development (R&D), and Maria Mirotsou, M.Sc., Ph.D., as Vice President of Discovery Biology.

Read More
May 16, 2023

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

Scribe Therapeutics Inc. today announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

Read More
More Headlines
Top